|
Evaluating Genetic Variation in Codon 72 of the p53 Gene and Its Role in the Incidence of Esophageal Cancer: A Case-Control Study
|
Reza Alipanah-Moghadam    , Zahra Farzaneh * , Taghi Amiriani , Sara Hoseinzadeh , Vadoud Malekzade , Abass Naghizadeh-Baghi |
| Department of Biochemistry, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran , zf066266@gmail.com |
|
|
Abstract: (32 Views) |
Background: p53 is one of the important gene in suppressing tumor formation. Polymorphism of the p53 gene in codon 72 is associated with an increased risk of the cancer. This study aimed to evaluate the p53 codon 72 polymorphism in esophageal cancer patients.
Methods: This case-control study was conducted using 32 patients with esophageal squamous carcinoma and 32 healthy control subjects. The polymorphism of the p53 gene was determined by using the PCR-RFLP method. Serum P53 levels were evaluated by the ELISA technique.
Results: Our results showed that the frequency of arginine–arginine, arginine–proline and proline-proline genotypes were 18.75, 37.5 and 43.75 in the patient group and 9.53, 56.25 and 34.37 in the control group, respectively. No significant difference was observed between the mean serum levels of P53 protein in the patient group and the control group.
Conclusion: The present study showed that the predominant polymorphism in patients with esophageal squamous cell carcinoma is the proline-proline polymorphism. Accordingly, it can be concluded that the proline-proline variant may play an important role in the pathogenesis of esophageal squamous cell carcinoma, and further investigation of it can lead to improved diagnostic and therapeutic strategies.
|
Article number: 5 |
| Keywords: Esophageal Cancer, Polymorphism, p53 Gene |
|
|
Full-Text [PDF 293 kb]
(19 Downloads)
|
Type of Study: article |
Subject:
Biochemistry
Received: 2025/07/19 | Accepted: 2025/08/12 | Published: 2025/09/27
|
|
|
|
|
|
|
| References |
1. Huang J, Lucero-Prisno III DE, Zhang L, Xu W, Wong SH, Siew C. Ng, et al. Updated epidemiology of gastrointestinal cancers in East Asia. Nat Rev Gastroenterol Hepatol. 2023;20(5):271-87. [ DOI:10.1038/s41575-022-00726-3] [ PMID] 2. Short MW, Burgers KG, Fry VTJAfp. Esophageal cancer. Am Fam Physician. 2017;95(1):22-8. 3. Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi VJCjog. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010-21. [ DOI:10.1007/s12328-020-01237-x] [ PMID] 4. Islami F, Kamangar F, Nasrollahzadeh D, Møller H, Boffetta P, Malekzadeh RJEJoC. Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran-a review. Eur J Cancer. 2009;45(18):3156-65. [ DOI:10.1016/j.ejca.2009.09.018] [ PMID] 5. Gholipour M, Islami F, Roshandel G, Khoshnia M, Badakhshan A, Moradi A, et al. Esophageal cancer in Golestan Province, Iran: a review of genetic susceptibility and environmental risk factors. Middle East J Dig Dis. 2016 ;8(4):249-266. [ DOI:10.15171/mejdd.2016.34] [ PMID] [ ] 6. Tarazi M, Chidambaram S, Markar SRJC. Risk factors of esophageal squamous cell carcinoma beyond alcohol and smoking. Cancers. 2021;13(5):1-13. [ DOI:10.3390/cancers13051009] [ PMID] [ ] 7. Lagares M, Silva K, Barbosa A, Rodrigues D, Costa I, Martins J, et al. Analysis of p53 gene polymorphism (codon 72) in symptomatic patients with atherosclerosis. Genet Mol Res. 2017;16(3): 1-9. [ DOI:10.4238/gmr16039721] [ PMID] 8. Sherr CJ, Bartek J. Cell Cycle-Targeted Cancer Therapies. Annu Rev Cancer Biol. 2017; 1 : 41-57. [ DOI:10.1146/annurev-cancerbio-040716-075628] 9. Pietsch E, Humbey O, Murphy M. Polymorphisms in the p53 pathway. Oncogene. 2006;25(11):1602-11. [ DOI:10.1038/sj.onc.1209367] [ PMID] 10. Shao Y, Tan W, Zhang S. P53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population. Dis Esophagus. 2008;21(2):139-43. [ DOI:10.1111/j.1442-2050.2007.00746.x] [ PMID] 11. Kafshdooz T, Tabrizi AD, Mohaddes Ardabili S, Kafshdooz L, Ghojazadeh M, Gharesouran J, et al. Polymorphism of p53 gene codon 72 in endometrial cancer: correlation with tumor grade and histological type. Asian Pac J Cancer Prev. 2014;15(22):9603-6. [ DOI:10.7314/APJCP.2014.15.22.9603] [ PMID] 12. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, et al. P53 codon 72 polymorphism and gastric cancer: A meta‐analysis of the literature. Int J Cancer. 2007;121(7):1481-6. [ DOI:10.1002/ijc.22833] [ PMID] 13. Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et al. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13(11):974. [ DOI:10.1038/s41419-022-05408-1] [ PMID] [ ] 14. Kampouraki E, Lourou M, Zervou MI, Ampazoglou E-D, Yachnakis E, Katzilakis N, et al. Role of CXCL12, TP53 and CYP1A1 gene polymorphisms in susceptibility to pediatric acute lymphoblastic leukemia. Oncology Letters. 2021; 22(3): 1-8. [ DOI:10.3892/ol.2021.12920] [ PMID] [ ] 15. Koushik A, Platt RW, Franco ELJCEB, Prevention. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev. 2004;13(1):11-22. [ DOI:10.1158/1055-9965.EPI-083-3] [ PMID] 16. Sul J, Yu G-P, Lu Q-Y, Lu M-L, Setiawan VW, Wang M-R, et al. P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Letters. 2006;238(2):210-23. [ DOI:10.1016/j.canlet.2005.07.004] [ PMID] [ ] 17. Jin X, Wu X, Roth JA, Amos CI, King TM, Branch C, et al. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis. 1995;16(9):2205-8. [ DOI:10.1093/carcin/16.9.2205] [ PMID] 18. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LgV, Ward LSJCl. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer letters. 2004;210(2):151-7. [ DOI:10.1016/j.canlet.2004.01.016] [ PMID] 19. Homady MH, Salih TS, Al-Jubori MM, Younus MD. Immunohistochemical and molecular studies of p53 and KRAS protein and their relations to colorectal carcinoma. Cihan Univ-Erbil Scient J. 2021;5(1):28-33. [ DOI:10.24086/cuesj.v5n1y2021.pp28-33] 20. Katkoori V, Goli R, Jia X, Callens T, Messiaen L, Jhala N, et al. Prognostic value of molecular alterations in high grade colorectal adenocarcinomas varies in African-Americans and Caucasians. Cancer Res. 2007;67(9):141. 21. Hoyos D, Greenbaum B, Levine AJ. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein. Cell Death Differ. 2022;29(5):938-45. [ DOI:10.1038/s41418-022-00980-7] [ PMID] [ ] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Ethics code: ARUMS.REC.93.64
Alipanah-Moghadam R, Farzaneh Z, Amiriani T, Hoseinzadeh S, Malekzade V, Naghizadeh-Baghi A. Evaluating Genetic Variation in Codon 72 of the p53 Gene and Its Role in the Incidence of Esophageal Cancer: A Case-Control Study. J Ardabil Univ Med Sci 2025; 25 (1) : 5 URL: http://jarums.arums.ac.ir/article-1-2518-en.html
|
.png)
.png)
